European Journal of Clinical Pharmacology

, Volume 74, Issue 9, pp 1187–1188 | Cite as

Similar effect of quercetin on CYP2E1 and CYP2C9 activities in humans?

  • Shingen Misaka
  • Kenju Shimomura
Letter to the Editor

Supplementary material

228_2018_2479_MOESM1_ESM.pdf (267 kb)
ESM 1 (PDF 267 kb)
228_2018_2479_MOESM2_ESM.docx (58 kb)
ESM 2 (DOCX 57 kb)


  1. 1.
    Bedada SK, Neerati P (2018) The effect of quercetin on the pharmacokinetics of chlorzoxazone, a CYP2E1 substrate, in healthy subjects. Eur J Clin Pharmacol 74:91–97. CrossRefPubMedGoogle Scholar
  2. 2.
    Kelly GS (2011) Quercetin. Monograph. Altern Med Rev 16:172–194PubMedGoogle Scholar
  3. 3.
    Bedada SK, Neerati P (2018) Evaluation of the effect of quercetin treatment on CYP2C9 enzyme activity of diclofenac in healthy human volunteers. Phytother Res 32:305–311. CrossRefPubMedGoogle Scholar
  4. 4.
    Izzo AA, Ernst E (2009) Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 69:1777–1798. CrossRefPubMedGoogle Scholar
  5. 5.
    Desiraju RK, Renzi NL, Jr., Nayak RK, Ng KT (1983) Pharmacokinetics of chlorzoxazone in humans. J Pharm Sci 72: 991–994Google Scholar
  6. 6.
    Nakamura K, Hirayama-Kurogi M, Ito S, Kuno T, Yoneyama T, Obuchi W, Terasaki T, Ohtsuki S (2016) Large-scale multiplex absolute protein quantification of drug-metabolizing enzymes and transporters in human intestine, liver, and kidney microsomes by SWATH-MS: comparison with MRM/SRM and HR-MRM/PRM. Proteomics 16:2106–2117. CrossRefPubMedGoogle Scholar
  7. 7.
    Ostlund J, Zlabek V, Zamaratskaia G (2017) In vitro inhibition of human CYP2E1 and CYP3A by quercetin and myricetin in hepatic microsomes is not gender dependent. Toxicology 381:10–18. CrossRefPubMedGoogle Scholar
  8. 8.
    Nguyen MA, Staubach P, Wolffram S, Langguth P (2014) Effect of single-dose and short-term administration of quercetin on the pharmacokinetics of talinolol in humans—implications for the evaluation of transporter-mediated flavonoid-drug interactions. Eur J Pharm Sci 61:54–60. CrossRefPubMedGoogle Scholar
  9. 9.
    Zhang S, Yang X, Morris ME (2004) Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 65:1208–1216. CrossRefPubMedGoogle Scholar
  10. 10.
    Ofer M, Wolffram S, Koggel A, Spahn-Langguth H, Langguth P (2005) Modulation of drug transport by selected flavonoids: involvement of P-gp and OCT? Eur J Pharm Sci 25:263–271. CrossRefPubMedGoogle Scholar
  11. 11.
    Kusuhara H, Furuie H, Inano A, Sunagawa A, Yamada S, Wu C, Fukizawa S, Morimoto N, Ieiri I, Morishita M, Sumita K, Mayahara H, Fujita T, Maeda K, Sugiyama Y (2012) Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. Br J Pharmacol 166:1793–1803. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pharmacology, School of MedicineFukushima Medical UniversityFukushimaJapan

Personalised recommendations